A controlled, randomized clinical trial is proposed to demonstrate the effectiveness of the experimental product in controlling hepato-pulmonary inflammation and neurovascular encephalic inflammation, which may constitute the etiopathogenic basis of persistent COVID. In addition, an individualized training program will be implemented for each participant in order to improve chronic symptoms and, consequently, their quality of life.
Subjects of both sexes.
Subjects over 18 and under 70 years of age who have had a SARS-CoV-2 infection diagnosed by PDIA.
Subjects with a history of SARS-CoV-2 infection who, three months after the onset of COVID-19, continue to experience symptoms lasting at least two months that cannot be explained by another cause. These symptoms may be newly developed after initial recovery from an acute COVID-19 episode or persist from the initial illness.
No history of sequelae from a severe acute illness.
Subjects with an underlying disease that explains the clinical manifestations.
Presence of chronic inflammatory diseases.
Subjects with acute infections.
Evidence of active thromboembolic disorder, defined as those receiving parenteral anticoagulant or thrombolytic treatment.